Solid Tumors
Conditions
Brief summary
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA) which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1, the researchers insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. Then the engineered cells are re-infused in the patients with tumors for curing the tumor patient or prolonging life.
Detailed description
This is a single-center, open-label, Phase I clinical study of TCR-T cells for the treatment of the recurrent/metastatic solid tumors patients who had failed standard therapy. TCR-T cells are expanded from peripheral blood, and after ex vivo modification, and extensive expansion, are reinfused to patients after non-myeloablative lymphocyte-depleting preparative regimen. The primary purpose of this study is to evaluate the safety and tolerability of TCR-T cells in patients with recurrent/metastatic solid tumors. The second purpose of this study is to preliminarily explore the effectiveness of TCR-T cells in patients with recurrent/metastatic solid tumors. Eligibility: Adults aging 18-70 who were failed to standard treatment or have no standard treatment with recurrent/metastatic solid tumors.
Interventions
BIOLOGICALTCR-T cells
patients will be administration of TCR-T cells
DRUGFludarabine
Part of the non-myeloablative lymphocyte-depleting preparative regime
Part of the non-myeloablative lymphocyte-depleting preparative regime
DRUGAlbumin-bound paclitaxel
Part of the non-myeloablative lymphocyte-depleting preparative regime
DRUGIL-2
Following cell infusion, the patient will be administration high-dose IL-2.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Have the willingness to communicate with investigator, be able to understand and follow the trail requirements, and voluntarily to participate in the trail; 2. 18 \ 70 years old (gender is not limited;) 3. The expected survival period is at least 3 months; 4. ECOG score of 0-1; 5. Patients with recurrent or metastatic solid tumors confirmed by histopathology; 6. Subjects who failed standard treatment in the past or have no standard treatment currently tor who are judged by the investigator to be unsuitable for current standard treatment for other reasons, and the objective imaging assessment is disease progression; 7. According to RECIST 1.1 standard, there is at least one measurable target lesion for efficacy evaluation; 8. NY-ESO-1 positive; 9. HLA type is HLA-A2 (except HLA-A\*0203);
Exclusion criteria
1. Female subjects who are pregnant or breastfeeding, or have a positive blood pregnancy test at baseline; 2. Subjects who have had severe allergic reactions to any drug or its components in this trial in the past; 3. Subjects who have received any investigational drug within 28 days before the infusion of TIL cells, or participated in another clinical study at the same time; 4. Subjects who have other known history of malignant tumors in the past 5 years, except for localized tumors that have been cured, including in situ cervical carcinoma, basal cell carcinoma of the skin, and in situ prostate carcinoma; 5. Patients who have received adoptive cell therapy in the past; 6. According to the judgment of the investigator, the condition of the subject is not suitable for this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity | up to Day28 | Dose Limiting Toxicity (DLT) is defined as patients with the adverse event (AE) or laboratory abnormality recognized by Investigators, and should be possibly related to TCR-T cells therapy |
| Adverse Event | up to 24 months | The severity and incidence of various adverse events and serious adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | up to 24 months | Objective response rate (ORR) is defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) is observed as best overall response |
| Progression free survival (PFS) | up to 24 months | PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first |
| Overall survival | up to 24 months | OS defined as the time from start of treatment to the date of death due to any cause |
Contacts
Primary ContactMeifang Li
Backup ContactZhiyong He
Outcome results
None listed